A detailed history of Pfg Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Pfg Advisors holds 4,150 shares of GILD stock, worth $351,048. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,150
Previous 3,013 37.74%
Holding current value
$351,048
Previous $220,000 29.09%
% of portfolio
0.02%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$63.15 - $72.88 $71,801 - $82,864
1,137 Added 37.74%
4,150 $284,000
Q1 2024

May 06, 2024

SELL
$71.58 - $87.29 $18,610 - $22,695
-260 Reduced 7.94%
3,013 $220,000
Q4 2023

Jan 19, 2024

SELL
$73.27 - $83.09 $6,447 - $7,311
-88 Reduced 2.62%
3,273 $265,000
Q3 2023

Oct 13, 2023

BUY
$73.94 - $80.67 $48,208 - $52,596
652 Added 24.07%
3,361 $251,000
Q2 2023

Jul 20, 2023

BUY
$76.01 - $86.7 $988 - $1,127
13 Added 0.48%
2,709 $208,000
Q1 2023

Apr 20, 2023

BUY
$77.31 - $88.08 $7,189 - $8,191
93 Added 3.57%
2,696 $223,000
Q4 2022

Jan 27, 2023

BUY
$62.32 - $89.47 $162,218 - $232,890
2,603 New
2,603 $223,000
Q3 2020

Oct 13, 2020

SELL
$62.1 - $78.08 $406,134 - $510,643
-6,540 Closed
0 $0
Q2 2020

Jul 16, 2020

BUY
$72.34 - $84.0 $12,659 - $14,700
175 Added 2.75%
6,540 $499,000
Q1 2020

Apr 29, 2020

SELL
$62.63 - $80.22 $4,822 - $6,176
-77 Reduced 1.2%
6,365 $517,000
Q4 2019

Jan 14, 2020

BUY
$61.62 - $67.78 $8,010 - $8,811
130 Added 2.06%
6,442 $424,000
Q3 2019

Oct 15, 2019

SELL
$62.51 - $69.0 $4,688 - $5,175
-75 Reduced 1.17%
6,312 $391,000
Q2 2019

Aug 05, 2019

SELL
$61.87 - $69.38 $12,374 - $13,876
-200 Reduced 3.04%
6,387 $427,000
Q1 2019

May 08, 2019

SELL
$62.53 - $70.05 $35,266 - $39,508
-564 Reduced 7.89%
6,587 $428,000
Q4 2018

Feb 19, 2019

BUY
$60.54 - $79.0 $20,523 - $26,781
339 Added 4.98%
7,151 $468,000
Q4 2018

Jan 18, 2019

BUY
$60.54 - $79.0 $412,398 - $538,148
6,812 New
6,812 $463,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Pfg Advisors Portfolio

Follow Pfg Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfg Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Pfg Advisors with notifications on news.